SCHEMBL1900933

SCHEMBL1900933

CCS(=O)(=O)c1ccc[c]c1O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
COMT P21964 1/20 0.39
PSIP1 O75475 1/20 0.38
APEX1 P27695 1/20 0.33
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
MAPT P10636 1/20 0.32
CYP2C9 P11712 1/20 0.32
HPGD P15428 1/20 0.32
CYP2C19 P33261 1/20 0.32
ATM Q13315 1/20 0.32
HSD11B1 P28845 2/20 0.31
ADRA2A P08913 1/20 0.31
ADRA2C P18825 1/20 0.31
ADRA1D P25100 1/20 0.31
ADRA1A P35348 1/20 0.31
ADRA1B P35368 1/20 0.31
PLCG1 P19174 1/20 0.31
GAA P10253 1/20 0.31
GABRA1 P14867 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17291026 0.78 PSIP1 (0.39) COMTPSIP1APEX1ADRA2AADRA2C
SCHEMBL9614697 0.78 PSIP1 (0.35) COMTPSIP1APEX1CYP1A2CYP3A4
SCHEMBL176809 0.78 TTR (0.38) COMTAPEX1CYP1A2MAPTHPGD
SCHEMBL1900932 0.73 PSIP1 (0.38) COMTPSIP1CYP1A2CYP2D6CYP2C9
SCHEMBL28680071 0.71 PSIP1 (0.59) COMTPSIP1APEX1CYP1A2CYP3A4
SCHEMBL672426 0.71 PSIP1 (0.48) COMTPSIP1APEX1CYP1A2CYP3A4
SCHEMBL1933231 0.71
SCHEMBL27562022 0.69 RORC (0.32) PSIP1
SCHEMBL14676186 0.69 PSIP1 (0.35) PSIP1
SCHEMBL8812999 0.68 HTR6 (0.49) CYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455477-B2 Therapeutic compounds MERCK SHARP & DOHME CORP. (US) 2013-06-04 US disclosed
US-20110207711-A1 Therapeutic Compounds MSD K.K. (JP) 2011-08-25 US disclosed
EP-2320907-A1 THERAPEUTIC COMPOUNDS Merck & Co., Inc. (US) 2011-05-18 EP disclosed
WO-2010017047-A1 THERAPEUTIC COMPOUNDS MERCK & CO., INC. (US) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207711-A1 Therapeutic Compounds WEE2, MARK3, WEE1 COMT 3431/4885PSIP1 2668/4885APEX1 4328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.